Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00593827 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
A Phase 2 study of Metastatic Breast Cancer, sponsored by R-Pharm.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
- 20
- Study locations
NCT00593827 is a Phase 2 study of Metastatic Breast Cancer that has completed, run by R-Pharm. The registered enrollment target is 176 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00593827, a Phase 2 study of Metastatic Breast Cancer, has completed, sponsored by R-Pharm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to determine the effects of the weekly regimen of ixabepilone dosing compared to the once every 3 week dosing regimen in participants with metastatic breast cancer.
Conditions Studied
Interventions
- DRUG Ixabepilone
Study Locations (20)
Arizona
- Hematology Oncology Associates - Phoenix
- Northern Arizona Hematology & Oncology Associates - Sedona
- Arizona Oncology Associates D.B.A. Hematology Oncology - Tucson
Florida
- Florida Cancer Institute - Hudson
- Ocala Oncology Center - Ocala
- Cancer Centers Of Florida, P.A - Ocoee
Missouri
- Missouri Cancer Associates - Columbia
- Kansas City Cancer Center, Llc - Kansas City
- Arch Medical Services, Inc. - St Louis
Indiana
- Central Indiana Cancer Centers - Carmel
- Hope Center - Terre Haute
Maryland
- Maryland Oncology Hematology, P.A. - Columbia
- Alliance Hematology Oncology, Pa - Westminster
Alabama
- Birmingham Hematology & Oncology Associates Llc - Birmingham
California
- Southwest Cancer Care - Murrieta
Illinois
- Cancer Care & Hematology Specialists Of Chicagoland - Niles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00593827
The ClinicalTrials.gov registry entry for NCT00593827 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (14% lower). The listed sponsor is R-Pharm, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ixabepilone is the first listed.
NCT00593827 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Arizona, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT00593827 about?
NCT00593827 is a clinical study titled "Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer". The purpose of this study was to determine the effects of the weekly regimen of ixabepilone dosing compared to the once every 3 week dosing regimen in participants with metastatic breast cancer.
What is the current status of trial NCT00593827?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2008-05. Estimated completion is 2010-08.
What conditions does trial NCT00593827 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT00593827?
The interventions under investigation include: Ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00593827?
This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00593827 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.